The Russian Ministry of Well being has issued a registration certificates for a radiopharmaceutical drug primarily based on radium-223 chloride (223Ra), used to deal with castration-resistant prostate most cancers with bone metastases and no visceral metastases. The drug was developed by the Federal State Unitary Enterprise (FSUE) «Federal Middle of Nuclear Medication Mission Design and Growth» of the FMBA of Russia.
“The energetic ingredient, radium chloride (223Ra), mimics calcium and kinds a fancy with the bone mineral hydroxyapatite. This enables the radium-223 isotope to selectively goal bone tissue, significantly metastatic prostate most cancers lesions within the bones. The vary of radiation may be very quick, minimizing the influence on surrounding wholesome tissues,” the drug’s directions clarify.
Based on heart, all preclinical and scientific trials had been carried out at main international facilities, confirming the drug’s effectiveness. Moreover, the standard and security of the drug are ensured by the uncooked supplies provided by FMBA Russia’s long-standing and dependable companion, the State Scientific Middle “Analysis Institute of Atomic Reactors.”
